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The term vulnerable atherosclerotic plaque was introduced by Muller et al 2, 3 2 decades ago, aiming to define those plaques that are prone to rupture and responsible for ACE. The precise mechanisms leading to plaque rupture remain to be elucidated, mainly because of the lack of an ideal animal model that could accurately reproduce human pathology. 4, 5 It has been established that ACE are not necessarily the result of slowly progressing luminal narrowing (ie, arterial stenosis) consequent to plaque growth, but are rather produced by the acute disruption (rupture or erosion) of atherosclerotic plaque followed by exposure of thrombogenic plaque components to the bloodstream and the subsequent thrombus formation. 1, 6 The latter triggers ACE by enhancing the degree of luminal stenosis or by producing distal arterial embolization. 1 The terms unstable plaque or high-risk plaque were introduced during the Meeting on Vulnerable Plaque in 2003, when these thrombose-prone plaques were described as containing a large thrombogenic lipid core or a calcified nodule covered by a fragile fibrous cap or a dysfunctional or interrupted endothelium.
of plaque vulnerability. The histopathological and molecular characteristics of typical vulnerable plaques, as defined by specialized literature, are summarized in Table 1 . 1, 4, [7] [8] [9] In simplified terms, vulnerable plaques are characterized by a thin inflamed fibrous cap covering a very large lipid core. However, ACE could be driven in 8% to 30% of patients by the disruption of the arterial endothelium overlying a lesion that is rich in smooth muscle cells (SMC) and extracellular matrix, with a relative paucity of inflammation, macrophages, and extracellular lipids. 10 Histopathological studies have also shown that 37% of the plaques are rupturing at the cap center, whereas 63% of them are fissured at the shoulder region. 11 Arterial stenosis is present in 50% of ACE and is superior to 75% at sites of plaque rupture. 10 The complexity of vulnerable plaques explains the absence of a consistent diagnosis profile and of an unequivocal specific treatment, although some studies have shown the benefit of preventive systemic treatments (ie, statins). 9 A wide range of medical imaging techniques have been proposed lately to characterize atherosclerotic plaques in vivo, starting with their morphological phenotyping 12, 13 and continuing with more complex methods allowing the detection of molecular components. 14, 15 The molecular imaging probes developed up-to-date are able to target an ample variety of vulnerability biomarkers involved in inflammation, thrombus formation, apoptosis, chemotaxis, angiogenesis, oxidative stress, collagen degradation, and so on. 14, 15 Despite this explosive development of molecular imaging probes, their extrapolation into clinically available agents and techniques is largely delayed. 15 During our previous studies, 2 peptides were identified by phage display and used to target the vascular cell adhesion molecule-1 (VCAM-1), as a biomarker of inflammation (targeted with a cyclic heptapeptide: R832), 16 and phosphatidylserine, as a biomarker of apoptosis (targeted with a linear hexapeptide: R826). 17 After conjugating them to paramagnetic contrast agents, the molecular imaging probes were validated on apolipoprotein E (ApoE) knockout (KO) mice by magnetic resonance imaging (MRI). However, the paramagnetic probes are known for their low relaxivity (ie, MRI efficacy, expressed as r 1 and r 2 , which is defined as the increase of relaxation rate [R 1 51/T 1 ; R 2 51/T 2 ] produced by 1 mmol/L of contrast agent [expressed in s/mmol per L]), which represents a serious drawback especially for molecular imaging of scarce targeted biomarkers in the diseased tissues. This motivated us to develop new molecular imaging probes by coupling the peptides to ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles that belong to a new class of MRI contrast agents currently under development for the improved molecular diagnosis of various pathologies. 18 The nanoparticles proposed by the present work expose functional groups at their surface 19 that are engaged in the covalent coupling of the vectorizing molecules and of the coating material, ie, polyethylene glycol (PEG). Such a nanoparticulate platform could assist the diagnosis of vulnerable atherosclerotic plaques by specifically targeting the characteristic biomarkers, ideally with a low background signal, high relaxivity, short imaging times after administration, and limited retention at the targeted sites. With these objectives in mind, the newly developed contrast media were characterized by a battery of physicochemical and biological trials, the final objective being to validate their MRI diagnostic potential. The uptake of USPIO-R832 and of USPIO-R826 by atherosclerotic plaque was assessed by MRI at 4.7 T on ApoE-KO mice and then analyzed in the context of various histological parameters characterizing the plaque vulnerability as largely described by the specialized literature and presented above.
Materials and Methods synthesis of usPiO derivatives
The peptides R832, R826, a control nonspecific peptide (NSP), and PEG were conjugated to USPIO, as previously described. 19 After USPIO synthesis, their hydrodynamic size and relaxivity at 60 MHz and at 300 MHz were evaluated (Methods in the online-only Data Supplement).
in Vitro Validation of usPiO derivatives

Estimation of the Apparent Dissociation Constant (K* d ) by ELISA and Competition for the Binding Sites
Recombinant human VCAM1/CD106 (R&D Systems, Abington, UK) and phosphatidylserine (1,2-Dipalmitoyl-sn-glycero-3-phospho-Lserine, sodium salt, Genzyme Pharmaceuticals, Liesta, Switzerland) were immobilized on microtiter plates. USPIO derivatives were incubated with the target at various concentrations. For competition and displacement experiments, fixed USPIO-R832 concentration (equal to its K* d ) was preincubated with increasing VCAM-1 concentrations in solution, followed by their transfer to VCAM-1 immobilized on ELISA plate; in the case of USPIO-R826, phosphatidylserine was first incubated with increasing concentrations of annexin V ( Sigma-Aldrich, Bornem, Belgium), followed by the addition of a fixed USPIO-R826 concentration (equal to its K* d ). The nanoparticles bound to the target were detected with rabbit anti-PEG monoclonal antibody (Epitomics/ Bio-Connect BV, TE Huissen, The Netherlands), biotinylated goat antirabbit IgG (Vector Table 1 . Histopathological and Molecular Characteristics of Typical Unstable Plaques, Serving as Markers of Plaque Vulnerability -Not necessarily large plaque, but prone to rupture and thrombogenic.
-The lipid/necrotic core is large and highly thrombogenic, whereas the cap is thin and contains rare smooth muscle cells and numerous macrophages.
-A soft core composed of cholesteryl esters, as opposed to crystalline cholesterol.
-The collagen producing smooth muscle cells are scarce, subsequent to their death by apoptosis.
-Collagen content versus lipid content is low.
-Macrophages are abundant, being the major source of collagen degrading proteinases and of tissue factor involved in thrombogenicity.
-The local inflammation, expressed by the accumulation of macrophages and of T-cells, is high.
-Neovascularization contributes to the recruitment of inflammatory cells into the plaques.
-Local plaque hemorrhage is predictive of clinical outcome.
-The role of cell death in the constitution of the necrotic core is not yet clarified, but several mechanisms of cell death may contribute to the size of the necrotic core.
Labconsult, Brussels, Belgium), and Vectastain ABC kit (Vector Labconsult), as previously described 20 (Methods in the online-only Data Supplement).
Studies of Binding to Cellular Models of Apoptosis and VCAM-1 Expression
Apoptosis was induced in Jurkat cells with camptothecin (MP Biomedicals, Brussels, Belgium). 17 Human umbilical vein endothelial cells (HUVEC) were stimulated with tumor necrosis factor- (Alexis Biochemicals, Zandhoven, Belgium). 16 The cells were then incubated with USPIO derivatives at an iron concentration of 4, 3, and 2 mmol/L. The iron concentration was determined by relaxometry (Bruker Minispec Mq60) after mineralization of the cell pellets in 5N HCl (Methods in the online-only Data Supplement).
Validation of usPiO derivatives on Apoe-KO Mice
MRI Studies
The experiments fulfill the requirements of the Ethical Committee of our institution. Female ApoE-KO mice (Guerbet, Aulnay-sous-Bois, France), aged 12 months, received a Western diet (0.21% cholesterol) for 2 to 3 months before the MRI studies. The mice were anesthetized with 50 mg/kg body weight, IP, of Nembutal (Sanofi, Brussels, Belgium). The USPIO derivatives (USPIO-R832, USPIO-R826, USPIO-NSP, and USPIO-PEG) were injected IV (caudal vein) at a dose of 0.1 mmol Fe/kg body weight.
The MRI experiments were performed on a 200 MHz (4.7 T) Bruker imaging system (Ettlingen, Germany) equipped with a vertical magnet and the microimaging device (Micro2.5AHS/RF, 25 mm coil). Images were acquired at the level of the abdominal aorta with T 2 -weighted rapid-acquisition relaxation-enhanced (RARE) (repition time/echo time53000/20 milliseconds, RARE factor54, number of experiments54, matrix5256X256, field of view52.3 cm, slice thickness 1 mm, 20 axial slices, spatial resolution590 mm, acquisition time512 minutes 48 seconds) and T 2 -star weighted fast low angle shot (FLASH) (repition time/echo time5175/1.88 milliseconds, number of experiments58, matrix5128X128, field of view52.5 cm, slice thickness 1.25 mm, 15 axial slices, spatial resolution5172 mm, acquisition time52 minutes 44 seconds) imaging protocols. A 3-dimensional-TOF sequence (repition time/echo time510/2 ms, flip angle520°, number of experiments52, field of view5424 cm, matrix525612864, slice thickness51 mm, 60 axial slices, spatial resolution5156156625 mm, acquisition time52 minutes 43 seconds) was used with the aim to confirm the anatomical location of the aorta in the image slice.
Signal intensity (SI) values for each time point were measured within regions of interest (ROIs) drawn manually by using the ImageJ image analysis software (National Institutes of Health) in the arterial wall of the abdominal aorta and in the liver. The internal border of the ROIs drawn on the arterial wall was outlined on precontrast images, where the arterial lumen is distinct from the arterial wall; the FLASH and the TOF images of the homologous axial slices were observed at the same time to compare the shape and the size of the lumen. The external border of the ROIs was delineated on postcontrast images, where the wall was contrasted and easier to distinguish. Identical ROI was then reproduced on precontrast and postcontrast images. The same operation was repeated on each of the 20 axial slices, where the arterial wall was thick enough for proper delineation. The histological staining of the harvested aorta samples by a protocol like Masson trichrome (as shown below) helps significantly to appreciate the size of the artery wall on magnetic resonance images. The standard deviation of noise was also measured in a region situated out of the animal's image. SI enhancement (Dsignal-to-noise ratio [SNR]%) was calculated for each axial image according to the following equation:
where: SI post 5postcontrast SI, and SI pre 5precontrast SI.
The percentage of black pixels in precontrast and 52 minutes postcontrast (thresholded to the precontrast level) RARE images of atherosclerotic plaques was evaluated by using the ImageJ software. The pixel thresholding is easily assisted by this software, which offers a parametric tool to select a certain range of pixel intensities. By using the analyze particle tool, it is possible to segment the selected pixels that are included in the drawn ROI ( Figure I in the online-only Data Supplement). The software generates then a set of data, including the percentage area occupied by the selected pixels in the total ROI. They were used in the present work to calculate the percentage difference of black pixels in postcontrast versus precontrast images.
Histochemistry of Atherosclerotic Plaques
After the MRI studies, samples of the aorta were harvested, fixed, paraffin embedded, and cut, as previously described. 16, 17 Before harvesting the aorta, the mice were euthanized by a lethal dose of Nembutal and the blood was removed by transcardial perfusion with 10 mL of PBS; this procedure prevents the endogenous iron staining by the Perls23,3-diaminobenzidine (DAB) protocol. Endogenous peroxidases, nonspecific epitopes, and endogenous biotin were blocked as described previously. 16, 17 For immunohistochemistry of VCAM-1 (biomarker of inflammation and of angiogenesis) and of caspase-3 (biomarker of apoptosis), the sections were incubated with rabbit anti-VCAM-1 polyclonal antibody (Santa Cruz Biotechnology, Heidelberg, Germany) or with rabbit anti-caspase-3 polyclonal antibody (Abcam, Cambridge, UK), followed by biotinylated goat antirabbit IgG (Vector Labconsult) and by the Vectastain ABC kit. Mac-1 (marker of macrophages) was immunolabeled with rat monoclonal antimouse MAC-1 (CD11b) antibody (AbD Serotec, Düsseldorf, Germany), followed by biotinylated rabbit antirat IgG (Vector Labconsult) and by the ABC kit. The final staining was performed with 0.05% DAB supplemented with 0.02% H 2 O 2 . Smooth muscle cells (SMC) were detected with rabbit monoclonal alpha SM actin antibody (E184) (Abcam), followed by Texas Red antirabbit IgG (Vector Labconsult).
For the staining of neutral lipids (triglycerides and cholesteryl esters) and of protein-bound cholesterol ( low-density lipoprotein), histological sections were incubated with 1% Nile blue (VWR International, Leuven, Belgium) and with 1% Sudan IV (Sigma-Aldrich) solutions.
The Massons trichrome staining of collagen and of cell cytoplasm and nuclei was carried out with the Accustain kit (SigmaAldrich).
The USPIO derivatives bound to the tissue were detected by staining with Perls working solution (1:1, 5% potassium ferrocyanide and 5% HCl). The tissue was then treated with 0.05% DAB, followed by 0.05% DAB supplemented with 0.033% H 2 O 2 .
USPIO-R832 and USPIO-R826 were colocalized with their targets by coincubation of aorta slices with rat anti-PEG monoclonal antibody (directed against the PEG coupled to USPIO) (Abcam) and with rabbit anti-VCAM-1 polyclonal antibody or with rabbit anticaspase-3 polyclonal antibody. They were then coincubated with Texas Red antirat IgG and with Fluorescein antirabbit IgG (both from Vector Labconsult). Histological slices were finally mounted in Vectashield mounting medium with 4,6 diamidino-2--phenylindole (Vector Labconsult). Please see the Methods in the online-only Data Supplement for the detailed description of histological protocols.
After staining, the slides were observed with a Leica DFC290 color digital camera mounted on a DM2000 Leica microscope (Leica Microsystems, Groot Bijgaarden, Belgium), equipped with a 100W high-pressure mercury burner for fluorescent samples. The histological biomarkers were then quantified with the ImageJ software by measuring the percentage of stained area; the analysis protocol is similar to that explained for the magnetic resonance images ( Figure  I in the online-only Data Supplement illustrates the analysis of some histological samples). The ImageJ analysis was carried out on several microphotographs belonging to the same aorta and the final result was averaged for each mouse.
Pharmacokinetics of USPIO Derivatives
The pharmacokinetics experiments were performed in compliance with the European Economic Community directive (86/609/ European Economic Community) on animal welfare, and they were carried out on 36 ApoE-KO mice (mean weight 35 g, Guerbet) and on 54 healthy male Swiss mice (mean weight 30 g, Janvier, Le Genest Saint Isle, France). The animals received an intravenous bolus injection of USPIO derivatives at a dose of 0.1 mmol Fe/kg body weight. All blood samples were taken under general anesthesia by inhalation of 5% of isoflurane (Forene) mixed with O 2 (1 L/min). Total iron concentrations in these samples were determined by inductively coupled plasma atomic emission spectrometry (Optima 3300 RL, Perkin Elmer, Courtaboeuf, France) and corrected for endogenous iron. Pharmacokinetic data were analyzed on Kinetica software (Innaphase, Champs de Marne, France). Elimination half-life (T 1/2 ), volume of distribution (V d ), and total plasma clearance (Cl tot ) were determined (Methods in the online-only Data Supplement).
results in Vitro characterization of usPiO derivatives
Physicochemical Characterization
The hydrodynamic diameter of USPIO derivatives is of 26 to 27 nm, as measured by photon correlation spectroscopy. The ratio r 2 /r 1 is not significantly different among the studied USPIO derivatives, but it is superior at 300 MHz (ie, 37 to 40 as compared with 5 to 6 at 60 MHz) ( Table I in the online-only Data Supplement).
Binding Affinity
The K* d of USPIO-R832 and of USPIO-R826 was of 3.7210
28 M and 7.7410 27 M, respectively, as determined by ELISA ( Figure 1A and 1B) . In blocking experiments, an IC 50 of 6.1410
29 M was found for VCAM-1 and of 3.5810 28 M was determined in the case of annexin V ( Figure 1C and 1D) .
The level of USPIO-R832 binding to HUVEC stimulated with tumor necrosis factor- was 170% to 90% higher than that to nonstimulated cells and 4 to 6 times superior to the binding of USPIO-PEG ( Figure 1E ) to stimulated cells. The binding of the latter was not significantly different between the stimulated and nonstimulated cells. The binding of USPIO-R826 to apoptotic Jurkat cells was 342% to 426% higher than to control cells and 7 to 8 times superior to the nonspecific compound USPIO-PEG ( Figure 1F ).
in Vivo characterization of usPiO derivatives
Molecular Imaging by MRI
The magnetic resonance images obtained on ApoE-KO mice with various USPIO derivatives (USPIO-R832, USPIO-R826, USPIO-NSP, and USPIO-PEG, the last 2 being control compounds) are shown in Figure 2 . Among the 10 mice injected with USPIO-R832, 6 were scanned by MRI for 90 minutes, whereas the other 4 were analyzed until 24 hours postinjection. The maximum negative contrast produced by USPIO-R832 in atherosclerotic plaque on RARE images occurred at 32 minutes postinjection. The maximum negative contrast observed on FLASH images occurred between 40 minutes and 80 minutes postcontrast. The total plaque area was measured on RARE images subsequent to the analysis of the 20 slices placed along the abdominal aorta (Table II in the online-only Data Supplement) and was found to be 0.871 mm 2 . In the group of USPIO-R826, 4 out of the 15 mice did not show an evident negative contrast enhancement probably because of the following reasons: a) 1 mouse did not show an apparent plaque on magnetic resonance images (confirmed by histology to have an area of 0.02 mm 2 ), b) 2 other mice seemed to present fibrous plaques on T 2 -weighted images (high SI), and 1 mouse showed a fibro-fatty lesion (slightly hyperintense SI). These mice were aged 9.32.9 months, were fed on a Western diet for 10 weeks, and their total plaque area measured 0.5180.343 mm 2 . They were not included in the measurement of DSNR%. In the rest of the group, USPIO-R826 produced a strong negative contrast of atherosclerotic plaque on RARE images, the maximum negative contrast occurring at 52 minutes postadministration. The plaque contrast on FLASH images was variable and often located around the vessel lumen. The maximum negative contrast occurred at 20 to 100 minutes postinjection. With the exception of 1 mouse, the negative contrast produced by USPIO-NSP was almost absent in the group of 6 mice studied for 92 minutes.
USPIO-PEG produced a belated negative contrast (90 minutes postinjection) on RARE images, which was variable in the experimental group. On FLASH images, the negative contrast was also delayed (60 minutes postinjection) and variable. The negative of the images obtained with USPIO-R832 (Figure 2 ) are shown in Figure 3A as an example of the positive differentiation that could be obtained simply by using the classical software of image analysis, thus helping the plaque discrimination.
The Kinetics of Contrast Enhancement on RARE Images of Aorta and Liver
The DSNR% of atherosclerotic plaque on RARE images obtained with USPIO-R832 decreased to 252%, 32 minutes postcontrast and remained constant until 92 minutes, being reproducible in the group of 6 mice ( Figure 3B ). The signal rose to 218%, 24 hours postcontrast, after attaining a minimum of 254%, 92 minutes postcontrast. The DSNR% in liver decreased to 234%, 33 minutes postcontrast and then remained at 231% until 92 minutes postcontrast. The signal decreased to 263%, 24 hours postcontrast.
In the group injected with USPIO-R826, the plaque signal decreased to 250%, 52 minutes postcontrast and remained constant until 92 minutes, being reproducible in the group of 6 mice; the signal rose to 239%, 24 hours postcontrast. In liver, the signal was at 231%, 24 hours postcontrast, after attaining a minimum (247%) 32 minutes postcontrast.
The DSNR% produced by USPIO-NSP in plaque attained a level of 216%, 24 hours postcontrast, after a minimum of 220%, 92 minutes postcontrast; the DSNR% was largely variable. The signal in liver ranged between 211% and 220%, but the minimum level (233%) was attained 24 hours postcontrast.
In the group injected with USPIO-PEG, the plaque signal rose to 26%, 24 hours postcontrast, after having attained a minimum of 237%, 221 minutes postcontrast. The DSNR% in liver ranged between 4% and 12%, but it decreased to 230%, 24 hours postcontrast and was largely variable.
Plaque Phenotyping in the Groups of Mice Injected With USPIO-R832 and USPIO-R826; Colocalization of USPIO-R832 and USPIO-R826 With Their Targets
The aorta samples harvested from the groups of mice injected with USPIO-R832 and USPIO-R826 were examined by histochemistry after the MRI studies. The histological samples shown in Figure 4 were harvested after the 90-minute MRI session. The comparative Perl' s-DAB staining of aorta samples collected from mice studied by MRI for 90 minutes or for 24 hours is shown in Figure II in the online-only Data Supplement, where the washout of contrast agents 24 hours after administration can be observed. A semiquantitative analysis of histological microphotographs was performed, and in some cases, the results were correlated with the distribution of black pixels in precontrast and postcontrast magnetic resonance images. The plaques were classified according to the American Heart Association (AHA) criteria.
The plaques in the group injected with USPIO-R832 ( Figure  4A ) ranged from type III to VIb, with a prevalence of type Va. In the group of mice injected with USPIO-R826 (Figure 4B ), the atherosclerotic lesions ranged from type I to VIb. Phenomena of plaque detachment could sometimes be observed at plaque shoulders, but no break in the fibrous cap could be noticed. Some hemorrhagic phenomena were observed at the base of most of the plaques, at the intima-media border. VCAM-1 was often identified around the necrotic cores, but it was not expressed by the foam cells. Caspase-3 is highly expressed by SMC and macrophages in early atherosclerotic lesions, but its immunostaining is generally weaker in the cytoplasm of the foam cells, where it seems to be present in the cell nuclei. In advanced atherosclerotic lesions, caspase-3 is mainly present around the necrotic/lipid cores. In only 1 mouse with type Va to VIb plaque, caspase-3 was intensely active in the plaque cap. Macrophages were frequently concentrated in the adventitia and seemed to invade the media, probably through the capillaries derived from vasa vasorum. In the mice not showing an evident MRI negative enhancement, the necrotic tissue was extended on large areas of the plaques. Both VCAM-1 and caspase-3 immunostaining (green fluorescence) colocalize with USPIO-R832 and USPIO-R826 binding (red fluorescence, labeling the PEG conjugated to USPIO), respectively. Colocalization is evident on merged microphotographs by the light green to orange color; the nuclei are stained in blue with 4,6 diamidino-2-phenylindole.
Semiquantitative Analysis of Histological Biomarkers
The ROI drawing followed by pixel thresholding and black pixel segmentation is illustrated in Figure 5A for precontrast and postcontrast images of the ApoE-KO mouse injected with USPIO-R832 shown in Figure 2 . Although not statistically different, the USPIO-R832 group was characterized by the largest global collagen content, which contributes to the plaque's stability ( Figure 5B ). The presence of higher low-density lipoprotein content may be a sign of plaques in evolution. The lower global collagen content in the group injected with USPIO-R826, together with more macrophages and neutral fats (and lower low-density lipoprotein), suggests that plaques have a more vulnerable phenotype. These results corroborate the MRI precontrast images, which present a wider distribution of black pixels ( Figure 5C ). This aspect is partly responsible for the lower percentage difference (%D) of black pixels in postcontrast versus precontrast images when compared with the USPIO-R832 group (P0.05). The %D of both USPIO-R832 and USPIO-R826 groups was not significantly different from that of the USPIO-NSP group because of the large variability of the latter. However, both groups were significantly different from USPIO-NSP when compared with the Perls'-DAB staining.
The SMC and macrophages in the plaque cap were visually evaluated and scored with quotations from 1 to 3. The ratio macrophages/SMC was then calculated and used as a criterion of plaque vulnerability ( Figure 5C, right histogram) . The USPIO-R832 group had the highest concentration of macrophages in the plaque cap, followed by the USPIO-NSP group.
The percentage distribution of black pixels in precontrast images was negatively correlated (r 2 520.851) with collagen content and positively correlated with macrophages (r 2 50.555) and neutral fats (r 2 50.899) ( Figure 6A and 6G ). This confirms the reliability of MRI in the characterization of plaque composition and of its phenotype.
The percentage distribution of black pixels in postcontrast images was positively correlated with Perls'-DAB staining (r 2 50.817), but the collagen content still had a contribution by a negative correlation (r 2 520.629) (Figure 6B and 6H) . Thus, the more stable the plaque phenotype (more collagen), the weaker the negative enhancement in postcontrast images.
The percentage area of the necrotic core was calculated by subtracting the area not stained by Nile blue from the total plaque area. In the USPIO-R832 group, the black pixels in postcontrast images were positively correlated with the size of the necrotic core (r 2 50.626) and with macrophages/SMC in the plaque cap (r 2 50.732) (Figure 6C, 6D, and 6I) . The USPIO-R826 group was characterized by a slight positive correlation with the size of the necrotic core (r 
Pharmacokinetic Parameters of USPIO Derivatives
Pharmacokinetic parameters (T 1/2 , V d , and Cl tot ) of USPIO derivatives (with the exception of USPIO-NSP) were determined in healthy Swiss mice and in ApoE-KO mice (Table 2) . USPIO-R832 and USPIO-R826 presented the same pharmacokinetics in healthy mice, which convinced us to assess only USPIO-R832 in ApoE-KO mice, taking it as a reference for peptide-conjugated USPIO derivatives. Although USPIO-PEG is characterized by a relatively faster elimination (22%-27% faster than functionalized contrast agents) and a more restricted distribution into the extravascular space (27%-33% smaller than functionalized contrast agents) when assessed in healthy mice, this situation is reversed in ApoE-KO mice, where the elimination is much slower for both tested USPIO derivatives. The T 1/2 of USPIO-PEG in ApoE-KO mice (443 minutes) is 36% slower than that of USPIO-R832 (285 minutes), whereas its V d (49 mL/kg) is 29% larger than that of the same functionalized contrast agents (38 mL/kg).
discussion
Superparamagnetic iron oxide nanoparticles (SPION) were already used to image atherosclerotic plaques, most of the imaging strategies being based on the passive targeting of macrophages, but also on the tools of active targeting. 21, 22 However, their development is limited by the negative contrast, which hampers their effect in tissues with low intrinsic signal, such as in the plaques with heavy calcification and blood degradation products. 22 This is probably the reason why works published on vulnerable plaque molecular targeting with SPION and the development of an imaging strategy for the stratification of patients at risk are quite scarce. In this context, our study tries to highlight the great potential that such a platform could offer for vulnerable plaque characterization, with an extrapolation to medicine being feasible.
in Vitro Properties of the Functionalized usPiO derivatives With implications for Atherosclerotic Plaque imaging
The diameter of USPIO derivatives studied in this work is inferior to that of capillary pores, making them perfectly compatible with capillary diffusion and accession of the targeted sites. They are characterized by a similar r 2 /r 1 ratio, which means that their NMR effect is comparable, whereas the produced MRI contrast might be attributable to the binding of the targeted biomolecules. As expected, the ratio r 2 /r 1 is superior at higher magnetic fields, which guarantees an excellent T 2 contrast in these conditions attributable to the minimal contribution of the T 1 effect.
When compared with previous IC 50 values (6.310 25 M for R832 and 1.4810
28 M for R826) obtained in competitive experiments, 16, 17 the binding affinity of R832 seems to be optimized by multivalent exposure on USPIO nanoparticles, whereas that of R826 appears to be disadvantaged by USPIO conjugation. Nevertheless, the K* d of both USPIO derivatives is in the nanomolar range, which indicates a good affinity for their target and warrants the specific imaging of molecular biomarkers with low background signal. The specific binding of USPIO-R832 and of USPIO-R826 to their target was furthermore confirmed in the present work by blocking experiments in the presence of soluble VCAM-1 and of annexin V, respectively.
The binding of USPIO-R832 to tumor necrosis factor--stimulated HUVEC was significantly higher in comparison with nonstimulated cells. Our previous studies 16 have shown that stimulated HUVEC express 162% more VCAM-1 than resting cells, which is in agreement with the binding data obtained in the present experiment. Based on the concentration of USPIO-R832 bound to HUVEC, the number of maximum binding sites was estimated to be of 9.310 4 /cell, which is in the range (610 3 -3.510 5 /cell) determined by other authors. 23, 24 USPIO-R826 interacted with apoptotic Jurkat cells at a much higher level as compared with either of the controls. The number of maximum binding sites on apoptotic cells was estimated to be of 1.510 5 to 6.510 5 /cell, which corroborates that (1.710 5 /cell) reported by other authors 25 and justifies the larger bound quantity of USPIO-R826 when compared with USPIO-R832. At high iron concentrations, the binding of USPIO-PEG to apoptotic cells was significantly higher than to control cells, although this interaction is much lower than that of USPIO-R826. Apoptotic cells are known to be sticky, the nonspecific binding of biomolecules being observed with antibodies 26 and with USPIO. 27 The cell binding experiments indicate that functionalized USPIO derivatives have a binding affinity 4 to 5 (in the case of USPIO-R832), up to 7 to 8 (in the case of USPIO-R826) times superior to that of nonspecific agent, USPIO-PEG, which also contributes to the specific imaging of targeted biomarkers thus limiting the background MRI signal and contributing to a more robust diagnosis.
in Vivo Behavior of Functionalized usPiO derivatives and Perspectives for the development of a diagnostic strategy of Vulnerable Atherosclerotic disease
Both USPIO-R832 and USPIO-R826 produced an early contrast enhancement of atherosclerotic plaque, which was reproducible and constant until 90 minutes after injection. An acquisition time at 20 to 30 minutes after contrast agent administration could be optimal, because after this time a nonspecific plaque accumulation may occur, as suggested by the control contrast agent, USPIO-PEG. This could be driven by the enhanced permeability and retention (EPR) effect in areas with leaky vasculature (ie, hypervascularity, enhanced permeability, and low washout), 28 the same as in tumors. The contrast related to the EPR effect is illustrated by USPIO-PEG, which is responsible for 70% of the specific plaque enhancement at very late imaging times after administration (ie, 221 minutes); 32 minutes after administration, the plaque contrast produced by USPIO-PEG was as low as 20% of the maximum enhancement attained with USPIO-R832 and USPIO-R826. It is possible that lower doses of contrast agent may produce a lower EPR effect, but such an effect needs at least 6 hours to be exerted as described in tumors. 29 In atherosclerotic plaques, contrast enhancement with various nonspecific USPIO formulations was described at high iron doses (ie, 1 mmol Fe/kg) 30 and at longer imaging times after administration (ie, 24 hours until 5 days), and it was associated with SPION uptake by macrophages but not as a result of the EPR effect. [30] [31] [32] However, this nonspecific imaging of atherosclerotic plaque was obtained with dextran coated USPIO formulations, whereas our USPIO derivatives were efficiently rendered stealthy by the covalent conjugation of PEG. 33 The stealth behavior of USPIO-PEG is reflected by the kinetics of plaque enhancement in our MRI experiments, where this contrast agent was not retained 24 hours after administration; this result was confirmed by histology following Perl' s-DAB staining. The contrast generated by simple plaque perfusion is illustrated by USPIO-NSP, which only attained 30% of the specific plaque enhancement, as observed with USPIO-R832 and USPIO-R826. We can conclude that plaque perfusion with nonspecific contrast agents (ie, USPIO-NSP and USPIO-PEG) is not sufficient to produce an MRI contrast comparable to that generated by specific agents (ie, USPIO-R832 and USPIO-R826), as it is demonstrated by the dynamics of plaque enhancement shown in Figure 3 .
The functionalized USPIO derivatives are characterized by a slow blood clearance mainly in ApoE-KO mice (285 minutes), but this is 36% faster than that of USPIO-PEG (443 minutes). At the same time, the nonspecific distribution into the extravascular space is 29% inferior to that of USPIO-PEG, which contributes to lower background signal and optimized specific MRI contrast of the targeted sites. In other words, the prolonged elimination half-life of USPIO-PEG in ApoE-KO mice does not contribute to the MRI plaque enhancement at early time points, ie, before 221 minutes postcontrast. Both USPIO-R832 and USPIO-R826 colocalized with their targets (VCAM-1 and apoptotic cells, respectively) on histological preparations, which attests for their specific binding and contrast enhancement of atherosclerotic plaques.
Our MRI studies suggest that all contrast agents are cleared by the liver, this process being faster for the targeted ones. This may be explained by the fact that hypercholesterolemia could predispose to liver injuries the ApoE-KO mice. 34 Our targeted contrast agents may thus be captured by the liver through a specific mechanism. The absence of SPION retention by plaque macrophages 24 hours after administration as opposed to the hepatic Kupffer cells may be explained by the different cell phenotype. In addition, the high blood pressure and velocity in the aorta may contribute to the faster clearance of contrast agents from atherosclerotic plaque when compared with the liver sinusoids.
USPIO-R826 did not produce a contrast enhancement in some of the mice. Histological inspection of their plaques showed a very large necrotic core, a relatively high collagen/ macrophages ratio (1.68 versus 1.26 for the rest of the group), and a lower caspase-3 expression (14.5% versus 21.41% for the rest of the group). Thus, the death cell events are less represented in these MRI hyperintense, collagen-rich plaques and justify the diminished capture of the contrast agent. Although these plaques were not globally enhanced, the negative contrast was evident around the artery lumen, which seemed to be enlarged in postcontrast images and colocalized with the expression of caspase-3 on histological slices. Interestingly, no hemorrhagic phenomena were observed in these mice.
The frequent VCAM-1 expression around the necrotic cores could be a sign of plaque vulnerability. VCAM-1 is probably expressed by macrophages, the migrated SMC, and by the endothelial cells of angiogenic capillaries, thus contributing to the plaque destabilization as previously described. 16, 35 As VCAM-1 is not expressed by foam cells, the imaging of atherosclerotic plaque will evidence those areas that do not contain foam cells. Caspase-3 seems to contribute to the remodeling of the arterial wall and of atherosclerotic plaque, 36 being highly expressed by SMC and macrophages in early atherosclerotic lesions. In the foam cells, caspase-3 seems to be mainly present in the cell nuclei, where it is responsible for chromatin condensation and DNA fragmentation. Caspase-3 becomes less active in advanced atherosclerotic lesions and is mainly present around the necrotic/lipid cores.
Although the ApoE-KO mouse model used in the present work display several characteristics of plaque vulnerability, the types VIb and VIc of atherosclerotic lesions, associated with wide hemorrhage and thrombosis according to the AHA classification were rather occasional. Therefore, other animal models may be employed to consolidate the utility of our functionalized contrast agents in the diagnosis of vulnerable atherosclerotic plaque. According to the specialized literature, several models would better meet the criteria of plaque vulnerability characteristic to humans, such as the brachiocephalic artery in ApoE-KO mice fed on high-fat diet, 37, 38 artificially induced plaque rupture in ApoE-KO mice subsequent to the acute insult, 38 the microminipig model fed on high-fat diet, 39 and the swine model of carotid atherosclerosis. 40 The first model holds our attention because of the facile implementation and the absence of a particular surgical procedure, but the plaque imaging needs MRI systems equipped with high magnetic fields and strong gradients to allow the visualization of a short and narrow vessel (2 mm long, 0.5 mm in diameter), 38 whereas the respiratory gating is prerequisite to avoid the respiration artifacts. The swine model is most relevant in terms of extrapolation to humans, but it requires considerable resources for implementation, such as accommodation, surgery, and access to the clinical MRI.
concluding remarks
The functionalized nanoparticle platforms (ie, SPION, gadolinium nanoparticlers, micelles, and liposomes) proposed in recent years represent a tremendous progress for medical imaging, opening optimistic promises in particular for the imaging of vulnerable atherosclerotic plaque, by making possible the visualization of cellular and molecular components responsible for the plaque's instability. [41] [42] [43] [44] [45] [46] [47] [48] [49] Nevertheless, these functionalized nanoparticles present several drawbacks that limit their perspectives for clinical applications.
Therefore, the development of an optimized imaging probe is still in progress and became a prerequisite for the patients suffering of cardiovascular diseases. The functionalized SPION platform proposed by the present work has been optimized by the small particle diameter (27 nm), the covalent conjugation of peptides and of PEG to the carboxyl groups exposed on the surface of USPIO, the biocompatible and stealth PEG coating, 50,51 the cost-effective and less immunogenic peptides, the high relaxivity and efficient contrast at low doses of administration, the relatively short blood half-life in comparison with other materials, and the washout from the targeted sites that prevents the eventual toxic effects. Certainly, they will need further improvement mainly with regard to the blood half-life that ideally should be even shorter, aiming to limit the background signal as much as possible.
Our results suggest that both specific contrast agents are able to detect plaques with a vulnerable morphology, but each one is detecting a specific environment. The USPIO-R832 group was characterized by the highest concentration of macrophages in the plaque cap, whereas the USPIO-R826 group presented plaques with lower global collagen content and more macrophages and neutral fats concentrated inside the plaque. Hemorrhagic phenomena observed at the intima-media border of most of the plaques could be a vulnerability characteristic of this model of atherosclerosis.
The molecular diagnosis may be hampered by the specific plaque composition, so it should not rely only on the contrast agent's effect. A complex MRI analysis is required, ie plaque size, intrinsic plaque contrast, and the pattern of molecular targeting. Specialized software could be conceived in order to analyze the complex information furnished by MRI and to help the physicians get the maximum information from the images and make the most realistic diagnosis. Such software should be able to quantify the black pixels in precontrast (representative of lipid-rich core and the presence of some types of hemorrhage, eg, chronic thrombus) 52, 53 and postcontrast images (representative of contrast agent binding), calculate their percentage difference, create maps of their distribution inside the plaque, invert the grey scale for easier visualization, subtract the precontrast information from the postcontrast one, and conclude with a simplified result based on the statistics of a large clinical trial. Several techniques were recently developed 54, 55 to convert the hyposignal produced by SPION agents to a positive contrast, but they rely on the susceptibility effects surrounding the regions with high iron concentrations being predisposed to various artifacts and inconsistent interpretation, at least in their actual stage of development. The simple inversion of the negative contrast with image analysis software, as it was illustrated by the present work, does not need a dedicated imaging technique and is proportional to the T 2 contrast produced by iron nanoparticles, rendering the molecular imaging confident and the plaque discrimination practical. This procedure could assist in the diagnosis of atherosclerotic plaque and could be combined with the subtraction of the precontrast image from the postcontrast one as previously described. 46 
sources of Funding
This work was financially supported by the Actions de Recherche Concertées (research contract no. 00/05-258 and 05/10-335), Nanodots fonctionnels pour la détection optique et magnétique, Fonds pour la formation à la Recherche dans l'Industrie et dans l'Agriculture, Fonds National de la recherche scientifique, European Network for cell imaging and tracking expertise and TELEVIE (grant number 7.4547.08) Programs of Research of the French Community of Belgium, and was performed in the framework of COST D38 
